Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Expert opinion on investigational drugs Ročník 9; číslo 12; s. 2903 - 2911
Hlavný autor: Kelland, Lloyd R
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England Ashley Publications Ltd 01.12.2000
Taylor & Francis
Predmet:
ISSN:1354-3784, 1744-7658
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.
AbstractList This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.
This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC(50)in the region of 100 nM) and tumour cell growth in vitro (typical IC(50)in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.
This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC 50 in the region of 100 nM) and tumour cell growth in vitro (typical IC 50 in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin's lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug's antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.
This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing Phase II single-agent trials and Phase I combination trials (with paclitaxel and cisplatin). Preclinically, flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). The drug showed in vivo antitumour activity (using iv., ip. or oral dosing) against a variety of human tumour xenografts, especially when administered on a regular daily, rather than weekly, schedule and most notably against prostate carcinoma, head and neck cancer, non-Hodgkin s lymphoma and leukaemia. The major toxicities observed in rodents were on the bone marrow and gastrointestinal tract. Pharmacokinetics were linear with dose and with a bi-exponential decline both in rodents and man. Oral bioavailability in rodents is in the region of 20%. Glucuronidation appears to be the major route of metabolism. Single-agent clinical trials have mainly used a 72 h continuous infusion schedule. Dose-limiting toxicities were diarrhoea and hypotension. Plasma concentrations in excess of those required for in vitro enzyme or cell growth inhibition are achievable. While there has been some evidence of single-agent antitumour activity (partial responses in a patient with renal cancer and another with gastric cancer), ongoing combination studies, especially with paclitaxel, where preclinical synergistic antitumour effects are observed, are promising. Doubt as to whether CDKs are the sole target responsible for the drug s antitumour effects have been raised by preclinical observations of apoptosis of non-cycling cells, effects on endothelial cells and non-CDK proteins, such as aldehyde dehydrogenase and glycogen phosphorylase, potent effects on PTEFb and transcription and its ability to directly interact with DNA.
Author Kelland, Lloyd R
Author_xml – sequence: 1
  givenname: Lloyd R
  surname: Kelland
  fullname: Kelland, Lloyd R
  organization: CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.lloyd@icr.ac.uk
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11093360$$D View this record in MEDLINE/PubMed
BookMark eNqFkc2OFCEUhYkZ4_zoC7gwtXJltVygqC6jCzNxfpJJZqNLQ2jqkmakoQVK028vZc-YOIueFTfk-84NnFNyFGJAQl4DXUAH_XvgneD9UiyGBbAFGyh_Rk6gF6LtZbc8qnMF2pk4Jqc531HK6NDxF-QYgA6cS3pCvl94_StuXXJj9O-assbGupRLY3bGu9COuMUwYijNDxd0xsaFtVu5ElNTYlPvMf2VZtiZD42ZUprpXHSZ8kvy3Gqf8dX9eUa-XXz5en7V3txeXp9_vmlNR3lpJbUS9EpSxkcNnNIeBisNgKaCIvaj7bjkEhEolT1yKcwKjBC9tGIUVvMz8nafu03x54S5qI3LBr3XAeOUVc8EZwD8SZDRGr5ksoJv7sFptcFRbZPb6LRTDz9XgeUeMCnmnNAq4-qbXQwlaecVUDWXpB5KUoMCpuaSqsoeqf_SD0mf9pILNqaN_h2TH1XROx-TTToYlxU_6H_8z1-j9mVtdEJ1F6cUaj2H1v8B2oG6Ow
CitedBy_id crossref_primary_10_1002_med_21510
crossref_primary_10_1074_jbc_M102060200
crossref_primary_10_1038_sj_bjc_6602243
crossref_primary_10_3390_cancers13174389
crossref_primary_10_1002_jps_22568
crossref_primary_10_1002_pbc_24073
crossref_primary_10_1517_13543784_12_4_593
crossref_primary_10_1016_j_nucmedbio_2014_08_008
crossref_primary_10_1007_s13596_013_0124_4
crossref_primary_10_1111_cbdd_13951
crossref_primary_10_1016_j_bmc_2019_115109
crossref_primary_10_1158_1078_0432_CCR_07_1347
crossref_primary_10_1002_ange_200200540
crossref_primary_10_1016_S1471_4892_01_00063_7
crossref_primary_10_1007_s10637_013_0002_4
crossref_primary_10_1016_S1368_7646_02_00141_3
crossref_primary_10_1038_s41598_017_05086_6
crossref_primary_10_1016_j_bmcl_2005_02_076
crossref_primary_10_1093_jnci_93_6_415
crossref_primary_10_1016_j_molcel_2014_04_013
crossref_primary_10_1038_nrd4504
crossref_primary_10_1007_s11095_019_2654_z
crossref_primary_10_1016_j_bmc_2006_10_063
crossref_primary_10_1016_j_prp_2023_154693
crossref_primary_10_3816_CLC_2008_n_024
crossref_primary_10_1007_s00894_005_0276_3
crossref_primary_10_1002_anie_200200540
crossref_primary_10_1002_ptr_5669
crossref_primary_10_1006_bcmd_2001_0452
crossref_primary_10_3390_molecules181114070
crossref_primary_10_1074_jbc_M102306200
crossref_primary_10_1007_s00210_024_03599_2
crossref_primary_10_1016_j_bmc_2007_05_022
crossref_primary_10_1016_j_chroma_2013_10_024
crossref_primary_10_1016_j_beha_2010_01_003
crossref_primary_10_1007_s00044_012_0232_6
crossref_primary_10_1016_j_ejmech_2009_04_004
crossref_primary_10_1016_j_biopha_2022_113754
crossref_primary_10_36290_csf_2019_001
crossref_primary_10_1016_j_fitote_2009_08_010
crossref_primary_10_1053_hupa_2003_45
crossref_primary_10_1038_sj_onc_1210123
crossref_primary_10_58920_sciphy01010013
crossref_primary_10_3389_fphar_2017_00109
crossref_primary_10_1002_jhet_2106
crossref_primary_10_1016_j_bcp_2003_07_007
crossref_primary_10_1016_j_canlet_2008_10_045
crossref_primary_10_1016_j_bmcl_2014_08_005
crossref_primary_10_1016_j_imlet_2012_10_004
crossref_primary_10_1186_1471_213X_11_33
crossref_primary_10_1186_1476_4598_5_76
crossref_primary_10_1186_s13045_017_0467_2
crossref_primary_10_1007_s13277_015_3493_0
crossref_primary_10_1016_j_ddmec_2004_10_003
crossref_primary_10_1517_13543784_2011_628985
crossref_primary_10_3389_fonc_2022_828438
crossref_primary_10_1002_med_1021
crossref_primary_10_1006_bcmd_2001_0428
crossref_primary_10_1016_j_ejmech_2013_05_037
crossref_primary_10_1096_fj_04_1646fje
crossref_primary_10_3389_fchem_2020_00276
crossref_primary_10_1097_01_cad_0000127332_06439_47
crossref_primary_10_4155_fmc_2016_0013
crossref_primary_10_1016_S1548_5315_11_70246_7
crossref_primary_10_1016_j_bmc_2019_01_027
crossref_primary_10_1016_j_ejmech_2009_11_001
crossref_primary_10_1080_14756366_2020_1740696
crossref_primary_10_1016_j_poly_2021_115638
crossref_primary_10_1007_s00210_024_03341_y
crossref_primary_10_1016_j_jconrel_2021_03_042
Cites_doi 10.1016/0962-8924(96)10034-9
10.1016/S0024-3205(98)00152-0
10.1074/jbc.M005267200
10.1182/blood.V91.2.458
10.1002/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B
10.1016/S0959-8049(99)00280-4
10.1182/blood.V92.10.3804
10.1006/bbrc.1994.1742
10.1074/jbc.C000446200
10.1038/sj.bjc.6690687
10.1200/JCO.2000.18.2.371
10.1182/blood.V96.2.393
10.1073/pnas.96.8.4325
10.1093/jnci/92.5.376
10.1073/pnas.93.7.2735
10.1016/S0014-5793(99)00773-5
10.1007/s002800050815
10.1074/jbc.M004485200
ContentType Journal Article
Copyright 2000 Ashley Publications Ltd. ISSN 1354-3784. 2000
Copyright_xml – notice: 2000 Ashley Publications Ltd. ISSN 1354-3784. 2000
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TM
7X8
DOI 10.1517/13543784.9.12.2903
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Nucleic Acids Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1744-7658
EndPage 2911
ExternalDocumentID 11093360
10_1517_13543784_9_12_2903
11199698
Genre Research Article
Journal Article
Review
GroupedDBID ---
00X
03L
0BK
0R~
0VX
29G
4.4
53G
5GY
AAMIU
AAOUU
AAPWH
AAPXX
ABBAB
ABBKH
ABEIZ
ABJYH
ABLKL
ACFUF
ACGFO
ACGFS
ADCVX
ADFCX
ADTOD
AECIN
AENEX
AEOZL
AEYQI
AGDLA
AGMLL
AIJEM
AIRBT
AIYSM
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BABNJ
BLEHA
CAZVN
CCCUG
CS3
DASJU
DAWQK
DKSSO
DU5
EBS
EJD
F5P
FERIO
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
M44
M4Z
O9-
P2P
RNANH
TAVEC
TFDNU
TFL
TFW
TZHSB
V1S
~1N
ABJNI
ABLIJ
ABXYU
ACIEZ
AFRVT
AGMHR
AQTUD
TASJS
TBQAZ
TDBHL
TERGH
TUROJ
AAYXX
ABECT
ADRBQ
AEIZR
AFFVI
AGVBG
AIHVM
AILGL
CITATION
EMOBN
IFJUI
LJTGL
LSO
S70
ABVAX
CGR
CUY
CVF
ECM
EIF
NPM
7TM
7X8
ID FETCH-LOGICAL-c503t-60f61ab6023da1300719f6c11a040ee7df53636ee10067e364cb1c4476f4d4fa3
IEDL.DBID TFW
ISICitedReferencesCount 119
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000166080800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1354-3784
IngestDate Thu Oct 02 06:02:31 EDT 2025
Fri Sep 05 09:34:20 EDT 2025
Thu Jan 02 21:49:17 EST 2025
Tue Nov 18 22:25:16 EST 2025
Sat Nov 29 03:54:20 EST 2025
Mon Oct 20 23:45:58 EDT 2025
Wed Jun 21 08:14:37 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c503t-60f61ab6023da1300719f6c11a040ee7df53636ee10067e364cb1c4476f4d4fa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Review-3
PMID 11093360
PQID 20364826
PQPubID 23462
PageCount 9
ParticipantIDs crossref_citationtrail_10_1517_13543784_9_12_2903
crossref_primary_10_1517_13543784_9_12_2903
proquest_miscellaneous_20364826
informaworld_taylorfrancis_310_1517_13543784_9_12_2903
proquest_miscellaneous_72432113
informahealthcare_journals_10_1517_13543784_9_12_2903
pubmed_primary_11093360
PublicationCentury 2000
PublicationDate 2000-12-01
PublicationDateYYYYMMDD 2000-12-01
PublicationDate_xml – month: 12
  year: 2000
  text: 2000-12-01
  day: 01
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert opinion on investigational drugs
PublicationTitleAlternate Expert Opin Investig Drugs
PublicationYear 2000
Publisher Ashley Publications Ltd
Taylor & Francis
Publisher_xml – name: Ashley Publications Ltd
– name: Taylor & Francis
References SEDLACEK HH (CIT0006) 1996; 9
SCHWARTZ GK (CIT0054) 1997; 3
SCHRUMP DS (CIT0024) 1998; 4
SCHWARTZ GK (CIT0055) 1999
CIT0031
CIT0012
CIT0034
MOTVVANI M (CIT0052) 1999; 5
DREES M (CIT0010) 1997; 3
SHAPIRO GI (CIT0025) 1999; 5
PATEL V (CIT0042) 1998; 102
BIBLE KC (CIT0038) 2000; 6
CARLSON BA (CIT0014) 1996; 37
CIT0035
CARLSON B (CIT0017) 1999; 59
KITADA S (CIT0028) 2000; 96
CIT0015
CIT0018
WERNER JL (CIT0058) 1998; 17
SHAPIRO G (CIT0057) 1999; 18
BYRD JC (CIT0022) 1998; 92
CIT0061
FRY DW (CIT0064) 2000; 2
SMITH V (CIT0039) 2000; 41
CIT0063
CIT0040
CIT0043
STADLER WM (CIT0059) 2000; 18
SENDEROWICZ AM (CIT0045) 1998; 16
PARKER BW (CIT0023) 1998; 91
ARGUELLO F (CIT0020) 1998; 91
BIBLE KC (CIT0036) 2000; 60
BENNET P (CIT0056) 1999; 18
KELLAND LR (CIT0009) 1999; 40
INNOCENTI F (CIT0044) 2000; 6
THOMAS J (CIT0048) 1997; 38
BIBLE KC (CIT0050) 1997; 57
CARLSON BA (CIT0013) 1996; 56
BIBLE KC (CIT0029) 1996; 56
LI Y (CIT0026) 2000; 5
MOTVVANI M (CIT0033) 2000; 6
CIT0047
CIT0005
CIT0027
CZECH J (CIT0041) 1995; 6
SENDEROWICZ AM (CIT0049) 2000; 19
CIT0004
References_xml – volume: 17
  start-page: 896
  year: 1998
  ident: CIT0058
  publication-title: Proc. ASCO
– ident: CIT0063
  doi: 10.1016/0962-8924(96)10034-9
– ident: CIT0043
  doi: 10.1016/S0024-3205(98)00152-0
– ident: CIT0027
  doi: 10.1074/jbc.M005267200
– volume: 6
  start-page: 924
  year: 2000
  ident: CIT0033
  publication-title: Clin. Cancer Res.
– volume: 91
  start-page: 458
  year: 1998
  ident: CIT0023
  publication-title: Blood
  doi: 10.1182/blood.V91.2.458
– ident: CIT0031
  doi: 10.1002/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B
– volume: 5
  start-page: 1876
  year: 1999
  ident: CIT0052
  publication-title: an. Cancer Res.
– volume: 18
  start-page: 1065
  year: 1999
  ident: CIT0056
  publication-title: Proc. ASCO
– ident: CIT0004
  doi: 10.1016/S0959-8049(99)00280-4
– volume: 91
  start-page: 2482
  year: 1998
  ident: CIT0020
  publication-title: Blood
– volume: 60
  start-page: 2419
  year: 2000
  ident: CIT0036
  publication-title: Cancer Res.
– volume: 2
  start-page: 40
  year: 2000
  ident: CIT0064
  publication-title: Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs
– volume: 92
  start-page: 3804
  year: 1998
  ident: CIT0022
  publication-title: Blood
  doi: 10.1182/blood.V92.10.3804
– volume: 5
  start-page: 2925
  year: 1999
  ident: CIT0025
  publication-title: Clin. Cancer Res.
– volume: 6
  start-page: 3400
  year: 2000
  ident: CIT0044
  publication-title: Clin. Cancer Res.
– ident: CIT0012
  doi: 10.1006/bbrc.1994.1742
– ident: CIT0018
  doi: 10.1074/jbc.C000446200
– ident: CIT0040
  doi: 10.1038/sj.bjc.6690687
– volume: 59
  start-page: 4634
  year: 1999
  ident: CIT0017
  publication-title: Cancer Res
– volume: 19
  start-page: 796
  year: 2000
  ident: CIT0049
  publication-title: Proc. ASCO
– volume: 57
  start-page: 3375
  year: 1997
  ident: CIT0050
  publication-title: Cancer Res
– volume: 18
  start-page: 371
  year: 2000
  ident: CIT0059
  publication-title: J. Clin. Oncol
  doi: 10.1200/JCO.2000.18.2.371
– volume: 4
  start-page: 2885
  year: 1998
  ident: CIT0024
  publication-title: Clin. Cancer Res.
– volume: 6
  start-page: 661
  year: 2000
  ident: CIT0038
  publication-title: Clin. Cancer Res.
– volume: 96
  start-page: 393
  year: 2000
  ident: CIT0028
  publication-title: Blood
  doi: 10.1182/blood.V96.2.393
– volume: 3
  start-page: 1467
  year: 1997
  ident: CIT0054
  publication-title: Clin. Cancer Res.
– ident: CIT0061
  doi: 10.1073/pnas.96.8.4325
– ident: CIT0005
  doi: 10.1093/jnci/92.5.376
– volume: 18
  start-page: 2013
  year: 1999
  ident: CIT0057
  publication-title: Proc. ASCO
– volume: 9
  start-page: 1143
  year: 1996
  ident: CIT0006
  publication-title: Int. J. Oncol
– ident: CIT0015
  doi: 10.1073/pnas.93.7.2735
– volume: 102
  start-page: 1674
  year: 1998
  ident: CIT0042
  publication-title: et al.:Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Clin. Invest.
– volume: 37
  start-page: 424
  year: 1996
  ident: CIT0014
  publication-title: Proc. AACR
– volume: 5
  start-page: 223
  year: 2000
  ident: CIT0026
  publication-title: Clin. Cancer Res.
– volume: 56
  start-page: 2973
  year: 1996
  ident: CIT0013
  publication-title: Cancer Res
– volume: 41
  start-page: 207
  year: 2000
  ident: CIT0039
  publication-title: Proc. AACR
– volume: 3
  start-page: 273
  year: 1997
  ident: CIT0010
  publication-title: Clin. Cancer Res.
– volume: 56
  start-page: 4856
  year: 1996
  ident: CIT0029
  publication-title: Cancer Res
– ident: CIT0034
  doi: 10.1016/S0014-5793(99)00773-5
– start-page: 26
  year: 1999
  ident: CIT0055
  publication-title: Proc. AACR/NCl/EORTC
– ident: CIT0047
  doi: 10.1007/s002800050815
– ident: CIT0035
  doi: 10.1074/jbc.M004485200
– volume: 16
  start-page: 2986
  year: 1998
  ident: CIT0045
  publication-title: STINSON SF etal.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. °rico/.
– volume: 6
  start-page: 31
  year: 1995
  ident: CIT0041
  publication-title: Int. J Oncol.
– volume: 40
  start-page: 125
  year: 1999
  ident: CIT0009
  publication-title: Proc. AACR
– volume: 38
  start-page: 222
  year: 1997
  ident: CIT0048
  publication-title: Proc. AACR
SSID ssj0020953
Score 1.9651964
SecondaryResourceType review_article
Snippet This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing...
SourceID proquest
pubmed
crossref
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2903
SubjectTerms Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
cancer
Clinical Trials as Topic
cyclin-dependent kinase
Cyclin-Dependent Kinases - antagonists & inhibitors
Flavonoids - pharmacology
Flavonoids - therapeutic use
flavopiridol
Humans
inhibitor
Neoplasms - drug therapy
Piperidines - pharmacology
Piperidines - therapeutic use
Title Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
URI https://www.tandfonline.com/doi/abs/10.1517/13543784.9.12.2903
https://www.ncbi.nlm.nih.gov/pubmed/11093360
https://www.proquest.com/docview/20364826
https://www.proquest.com/docview/72432113
Volume 9
WOSCitedRecordID wos000166080800010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAWR
  databaseName: Taylor and Francis Online Journals
  customDbUrl:
  eissn: 1744-7658
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0020953
  issn: 1354-3784
  databaseCode: TFW
  dateStart: 19940101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELag6oELlPIqj-ID6oUsxLHXXnNDqBEHVOUQRC7I8vqhroh2q91Npfx7PPYm4dUc6N1jrb0znvnsmW8QekMJ0wEl24yUXGaMllCsbGjmdKGFNFYWLnYt-SIuLorFQs6GC7duSKsEDO0TUUQ8q8G4dZk6kOREvCc0Z1QU7J2Em7yJjGSfIayHjL759NsWbwGVWsRbOctg_FAz8-8pfvNLRwNr6eU2B-sPJtOb49Hol6YPbruiI3R_iEjxx6RCD9EdVx-js1mitF6P8HxXodWN8Bme7ciu14_Q9-lSXzdXVVvZZjnCIZzEvgoRJTZrKLrMNk12e_yjqoPHxFV9WZXhGGlx32AgBG2jUKrQ_IBN4ovCUOi06h6jr9Pz-afP2dCyITP5mPYZH3tOdMlDJGA1vJQJIj03hOhwWDgnrM8pp9w5Am7SUc5MSQxjgntmmdf0CTqom9o9Q9gIA_x3NnfUM0FtIbUlwpuiDEGelOIEkc0PU2bgM4e2GksFuCbsqtrsqpKKTBTs6gl6u5W5Smwee0fnf-mBGky82yvHf9UV1ce7F58apSi6T_D1RqtUsHJ4utG1a1adis_FAQnePEJMGA1gPszxNKnjboHAGEb5-Pn_ftYLdC8SEMQknpfooG9X7hU6NNd91bWn6K5YFKfR8n4CxEwpDw
linkProvider Taylor & Francis
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Nb9MwFLfQQIILjO8BYz6gXWigrh075jZNq4YoVQ9F7IIsxx9aRJVMSTqp_z1-TtrytR7g7mfFznv2-9l-vx9CbyhhOqBkm5Ccy4TRHIqVDU2czrSQxsrMRdWSiZhOs4sLOet1Tpv-WSVgaN8RRcS1GoIbDqM7uR4i3hOaMioy9k7CUd5IAtvnbZCmA_Q1H3_dIC4gU4uIK2UJGPRVM3_v45edab_nLb3cvML6jcv05ow07kzjB_89pn10v09K8UnnRQ_RLVc-QsezjtV6NcDzbZFWM8DHeLblu149Rt_GC31dXRV1YavFAIeMEvsiJJXYrKDuMlnr7Lb4e1GGTRMX5WWRh5Wkxm2FgRO0jkZdkeYHbDrKKAy1TsvmCfoyPpufnie9akNi0iFtEz70nOich2TAargsE0R6bgjRYb1wTlifUk65cwR2Skc5MzkxjAnumWVe06dor6xK9xxhIwxQ4NnUUc8EtZnUlghvsjzkeVKKA0TWf0yZntIclDUWCqBNmFW1nlUlFRkpmNUD9HZjc9UReuxsnf7hCKqP8manHf_ZWVQbj198p5Wi6C7Do7VbqRDocHujS1ctGxVvjAMYvLmFGDEa8Hzo41nnj9sBAmkY5cMX__pZR-ju-fzzRE0-Tj-9RPciH0F80_MK7bX10h2iO-a6LZr6dQzAH2JDLEo
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbQghAXWN7La31Ae6Fh69qxY24IiECsqh6K2AuyHD-0EVVSJelK_fd4nLTltT3A3WPFzoxnPnvmG4ReUsJ0QMk2IQWXCaMFFCsbmjidaSGNlZmLXUvOxHSanZ_L2XDh1g5plYChfU8UEc9qMO6l9X23HiJOCU0ZFRl7LeEmbyKB7PN6iJtT0Op5_nULuIBLLQKulCUgMBTN_H2OXxzT4UBberFNwvqNyvTqgDQ6pvzO_y7pEN0eQlL8ttehu-iaq-6hk1nPab0e4fmuRKsd4RM827Fdr--jb_lCX9bLsiltvRjhEE9iX4aQEps1VF0mmy67Hf5eVsFl4rK6KItwjjS4qzEwgjZRqC_RfINNTxiFodJp1T5AX_IP83cfk6FnQ2LSMe0SPvac6IKHUMBqeCoTRHpuCNHhtHBOWJ9STrlzBPyko5yZghjGBPfMMq_pQ3RQ1ZV7jLARBgjwbOqoZ4LaTGpLhDdZEaI8KcURIpsfpsxAaA59NRYKgE3YVbXZVSUVmSjY1SP0aiuz7Ok89o5O_9ADNdh4u1eO_6wrqouXL77vlKLoPsHjjVapYObwdqMrV69aFd-LAxS8eoSYMBrQfJjjUa-OuwUCZRjl4yf_-lnH6Obsfa7OPk0_P0W3IhlBTOh5hg66ZuWeoxvmsivb5kU0vx-1Kyr8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Flavopiridol%2C+the+first+cyclin-dependent+kinase+inhibitor+to+enter+the+clinic%3A+current+status&rft.jtitle=Expert+opinion+on+investigational+drugs&rft.au=Kelland%2C+L+R&rft.date=2000-12-01&rft.issn=1354-3784&rft.volume=9&rft.issue=12&rft.spage=2903&rft.epage=2911&rft_id=info:doi/10.1517%2F13543784.9.12.2903&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1354-3784&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1354-3784&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1354-3784&client=summon